Oregon Reinstates Drug Price Reporting for Insurance Compliance

On February 13, the Oregon Department of Consumer and Business Services announced the withdrawal of Bulletin DFR 2024-3, reinstating the requirement for manufacturers to submit annual price increase reports. This action is part of the Oregon Drug Price Transparency Program, following Bulletin No. DFR 2026-2, which takes immediate effect. The reinstatement aligns with regulatory compliance requirements and impacts those involved in insurance, underwriting, and claims management within the state.

The department responded to ORS 646A.689 and a Ninth Circuit ruling that overturned an earlier decision by the U.S. District Court in the case of Pharmaceutical Research & Manufacturers of America v. Stolfi. This reversal led to the resumption of mandatory annual reporting in compliance with the state's legal framework, which affects insurers, brokers, and other industry stakeholders tasked with regulatory compliance and risk management.

The October 31, 2025, decision by the Ninth Circuit mandates that the Department resume collecting these vital price increase reports from pharmaceutical manufacturers. Insurance carriers and providers must note the change, as it directly impacts their operations and compliance strategies. Adhering to state regulations on drug pricing transparency is crucial for effective risk management and maintaining industry standards in Oregon.